{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Screening Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from a footnote in the Schedule of Activities (SoA) to Section 8 for details on procedures at US screening sites."
      },
      {
        "id": "ref_2",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference to section detailing potential risks and mitigation measures due to the COVID-19 vaccine."
      },
      {
        "id": "ref_3",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference from the risk mitigation strategy table to the dose modification or discontinuation section."
      },
      {
        "id": "ref_4",
        "name": "Adaptive Features Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference to the table describing adaptive design features of the study."
      },
      {
        "id": "ref_5",
        "name": "Dose Modification Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference from the adaptive features table to the dose modification criteria table."
      },
      {
        "id": "ref_6",
        "name": "Exclusion Criteria Reference for Blood Donation",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from lifestyle considerations regarding blood donation restrictions to the main exclusion criteria section."
      },
      {
        "id": "ref_7",
        "name": "Contraception Guidance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference to the section describing appropriate contraceptive methods."
      },
      {
        "id": "ref_8",
        "name": "Inclusion Criteria Reference for Contraception",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference to inclusion criteria for start times of contraceptive methods."
      },
      {
        "id": "ref_9",
        "name": "SoA Reference for Discontinuation Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference to the Schedule of Activities for data to be collected at the time of study intervention discontinuation."
      },
      {
        "id": "ref_10",
        "name": "Pregnancy Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference to the pregnancy section regarding discontinuation from study intervention."
      },
      {
        "id": "ref_11",
        "name": "SoA Table Reference for Discontinuation",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to the SoA table for samples and data to be collected at the time of study intervention discontinuation."
      },
      {
        "id": "ref_12",
        "name": "QTc Withdrawal Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal",
        "description": "Reference to the discontinuation section for QTc withdrawal criteria."
      },
      {
        "id": "ref_13",
        "name": "Clinical Lab Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to the section listing the clinical laboratory tests to be performed."
      },
      {
        "id": "ref_14",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Reference to the section outlining procedures for recording, evaluating, and reporting AEs and SAEs."
      },
      {
        "id": "ref_15",
        "name": "Lost to Follow-up Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference to the section defining 'lost to follow-up'."
      },
      {
        "id": "ref_16",
        "name": "Genetic Testing Non-use Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference clarifying that biobanked samples will not be used for genetic testing."
      },
      {
        "id": "ref_17",
        "name": "Molybdenum Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference to details of molybdenum measurement in food, drinks, urine, and feces."
      },
      {
        "id": "ref_18",
        "name": "Biomarker Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference to the pharmacodynamics section for details on specific biomarkers."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigatorâ€™s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_2",
        "text": "Reference to the Investigator's Brochure (IB) for data from previous studies.",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Outpatient Period (Day 9 to Day 23) may be extended up to an additional 14 days with Investigator approval.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 4. Adaptive Protocol Features",
        "pageNumber": 27
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_5",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol Approval Date",
        "amendmentNumber": "N/A"
      },
      {
        "id": "ver_2",
        "versionNumber": "Amendment 1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Protocol Amendment 1 Approval Date",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 2",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Protocol Amendment 2 Approval Date",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "Amendment 3",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Protocol Amendment 3 Approval Date",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 (US) Approval Date",
        "amendmentNumber": "Amendment 3.1 (US)"
      }
    ],
    "summary": {
      "referenceCount": 18,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}